TMC435-TiDP16-C123 - A Study in Healthy Volunteers Investigating the Pharmacokinetic Interaction Between TMC435 and the Antiretroviral Agents Efavirenz and Raltegravir

NCT01241773 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

48

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatitis C Virus

Interventions

DRUG: raltegravir
DRUG: TMC435 + raltegravir
DRUG: TMC435
DRUG: TMC435 + efavirenz
DRUG: TMC435
DRUG: efavirenz

Sponsor

Tibotec Pharmaceuticals, Ireland